Piramal starts phase-II trials for type-2 diabetes drug
22 Sep 2010
Piramal Life Sciences today said it has started phase-II clinical trials of a molecule, for treatment in diabetes, in Europe and India.
The company has initiated the phase-II study of 'P1736-05', an insulin sensitising compound, being developed for the treatment of type-2 diabetes, in India and Europe, Piramal reported in a filing to the Bombay Stock Exchange (BSE) today.
Piramal Life Sciences managing director, Somesh Sharma said the commencement of phase-II trials of P1736-05 in India and Europe spoke of the company's efforts in building a diversified and strong pipeline of products to address unmet medical needs.
He further added that the molecule was likely to provide an effective therapeutic option to type-2 diabetes patients.
The World Health Organisation (WHO) says, Type-2 diabetes, diabetes mellitus is a health crisis of global proportions with a projected incidence rate of 300 million by 2025.
Type-2 or non-insulin dependent diabetes patients constitute around 95 per cent of the global diabetic population.
